136 related articles for article (PubMed ID: 11745924)
1. Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations.
Sarmati L; Nicastri E; Parisi SG; D'Ettorre G; Narciso P; Mancino G; Gallo I; Abbadessa V; Dalle NE; Traina C; Vullo V; Andreoni M
J Med Virol; 2001 Dec; 65(4):631-6. PubMed ID: 11745924
[TBL] [Abstract][Full Text] [Related]
2. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
Calvez V; Costagliola D; Descamps D; Yvon A; Collin G; Cécile A; Delaugerre C; Damond F; Marcelin AG; Matheron S; Simon A; Valantin MA; Katlama C; Brun-Vézinet F
Antivir Ther; 2002 Sep; 7(3):211-8. PubMed ID: 12487389
[TBL] [Abstract][Full Text] [Related]
3. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
[TBL] [Abstract][Full Text] [Related]
4. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
Mouroux M; Descamps D; Izopet J; Yvon A; Delaugerre C; Matheron S; Coutellier A; Valantin MA; Bonmarchand M; Agut H; Massip P; Costagliola D; Katlama C; Brun-Vezinet F; Calvez V
Antivir Ther; 2001 Sep; 6(3):179-83. PubMed ID: 11808752
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
6. Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.
Milazzo L; Rusconi S; Testa L; La Seta-Catamancio S; Galazzi M; Kurtagic S; Citterio P; Gianotto M; Grassini A; Adorni F; d'Arminio-Monforte A; Galli M; Moroni M
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):101-3. PubMed ID: 10534153
[No Abstract] [Full Text] [Related]
7. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
Coakley EP; Gillis JM; Hammer SM
AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
[TBL] [Abstract][Full Text] [Related]
9. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
10. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
13. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
14. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
Gibson RM; Nickel G; Crawford M; Kyeyune F; Venner C; Nankya I; Nabulime E; Ndashimye E; Poon AFY; Salata RA; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
Infect Dis Poverty; 2017 Dec; 6(1):163. PubMed ID: 29202874
[TBL] [Abstract][Full Text] [Related]
15. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
Mancinelli S; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Amici R; Pirillo MF; Scarcella P; Marazzi MC; Vella S; Palombi L; Giuliano M
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):737-42. PubMed ID: 27067142
[TBL] [Abstract][Full Text] [Related]
16. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
17. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.
Maguire M; Gartland M; Moore S; Hill A; Tisdale M; Harrigan R; Kleim JP
AIDS; 2000 Jun; 14(9):1195-201. PubMed ID: 10894284
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.
de Mendoza C; Ramos JT; Ciria L; Fortuny C; García FJ; de José MI; Asensi F; Soriano V
HIV Clin Trials; 2002; 3(1):9-16. PubMed ID: 11819180
[TBL] [Abstract][Full Text] [Related]
19. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y
J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320
[TBL] [Abstract][Full Text] [Related]
20. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
